Physician profile
Jones Samuel
NPI 1164429437
$206,565.94
in general payments reported to CMS, 2019-2025
43 companies · $50K in 2025
The $50K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $18K · 2021: $14K · 2022: $28K · 2023: $31K · 2024: $45K · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $103K · Food and Beverage: $11K · Travel and Lodging: $8,999 · Consulting Fee: $2,960 · Education: $90.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $102,597.50 |
| Food and Beverage | $11,196.85 |
| Travel and Lodging | $8,998.94 |
| Consulting Fee | $2,960.00 |
| Education | $90.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $59,487.81 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $58,589.50 | 2019-2025 | Soliris, Ultomiris |
| Vifor Pharma, INC. | $28,598.58 | 2019-2024 | Veltassa, Korsuva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20,685.10 | 2019-2025 | Jardiance |
| Akebia Therapeutics INC | $14,807.55 | 2019-2025 | Vafseo, Auryxia |
| Lilly USA, LLC | $7,637.72 | 2023-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $2,586.01 | 2022-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $2,218.30 | 2019-2025 | Velphoro, Velphoro, Optiflux |
| Mallinckrodt Hospital Products INC. | $1,505.73 | 2020-2025 | Acthar, Terlivaz |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $1,369.03 | 2019-2025 | Jynarque |
| Otsuka America Pharmaceutical, INC. | $1,247.98 | 2019-2025 | Jynarque |
| Amgen INC. | $1,207.68 | 2019-2025 | Krystexxa, Tavneos |
| Astrazeneca Pharmaceuticals LP | $1,046.13 | 2019-2025 | Farxiga, Lokelma |
| Aurinia Pharma U.S., INC. | $858.30 | 2022-2025 | Lupkynis |
| Baxter Healthcare | $676.94 | 2019-2024 | Renal - Acute, Renal - Pd |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jones Samuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.